PSTV Plus Therapeutics
- 2.3000
- +0.1300+5.99%
Plus Therapeutics News
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Plus Therapeutics (PSTV) and Argenx Se (ARGX)
Plus Therapeutics Has Acquired Assets For The Synergistic Leptomeningeal Metastases Diagnostic Platform, Financial Terms Not Disclosed; Topline Clinical Trial Data On The FORESEE Trial, Met Its Primary Endpoint Of Clinical Utility
CNSide can significantly improve LM diagnostic accuracy and the market size for Plus' lead LM radiotherapeutic candidate rhenium (Re186) obisbemeda Company summarized topline data from the FORESEE cli
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data From the FORESEE Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) today announces it will host an investor call on Thursday, May 9th, 2024 at 8:30 AM ET to discuss the strategic acquisition of the CNSide cerebrospinal fluid (CSF) testing assets.
Press Release: Plus Therapeutics Announces Private Placement Financing of up to $18 Million
Plus Therapeutics Announces Private Placement Financing of up to $18 Million $6.5 million in upfront gross proceeds with the potential to receive up to an additional $11.5 million in potential warran
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs. The
Plus Therapeutics Says 'Plus Now Has $23 Million in Active Awards Support for the Company's Targeted Radiotherapeutic Pipeline'
Plus Therapeutics Says 'Plus Now Has $23 Million in Active Awards Support for the Company's Targeted Radiotherapeutic Pipeline'
Press Release: Plus Therapeutics Receives $3 Million Award Recommendation From the United States Department of Defense
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic p
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scient
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)
Plus Therapeutics Faces Nasdaq Delisting Over Equity Shortfall
Plus Therapeutics CEO's Insightful Presentation Now Available
Scania Accelerates Deployment of Autonomous Hub-to-hub Transport
SÖDERTÄLJE, Sweden, March 12, 2024 /PRNewswire/ -- Launch of Autonomous Commercial Pilot Programme, with plans for autonomous solution powered by the leading technology stack from Plus. Scania is
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
A total of 18 patients have been dosed in the trial to date Company anticipates moving into Cohort 6 in Q2 2024 following standard safety review AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics,
Buy Rating Affirmed for Plus Therapeutics Amid Strong Financials and Promising Clinical Trials
Plus Therapeutics Is Worried About This – Should You Be Worried Too?
Earnings Call Summary | Plus Therapeutics(PSTV.US) Q4 2023 Earnings Conference
The following is a summary of the Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript:Financial Performance:Plus Therapeutics reported a decrease in cash reserves to $8.6 million by the en
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
Analysis
Price Target
No Data
